Seres Therapeutics to Present at Canaccord Genuity 41st Annual Growth Conference

Rhea-AI Summary

Seres Therapeutics (Nasdaq: MCRB) announced that Eric Shaff, President and CEO, will discuss the company at the Canaccord Genuity 41st Annual Growth Conference on August 11 at 9:00 a.m. ET. A webcast replay will be available on the company's website two hours post-event and will be archived for 21 days.

Seres Therapeutics specializes in microbiome therapeutics with its SER-109 program being a first-ever positive pivotal clinical result for a targeted microbiome drug candidate. The company is also advancing SER-301 and SER-155 in clinical studies.

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Eric Shaff, President and Chief Executive Officer of Seres Therapeutics, will participate in a discussion at the Canaccord Genuity 41st Annual Growth Conference on Wednesday, August 11 at 9:00 a.m. ET.

A webcast replay will be available on the Seres website beginning approximately two hours after the event and will be archived for approximately 21 days.

About Seres Therapeutics

Seres Therapeutics, Inc. (Nasdaq: MCRB) is a leading microbiome therapeutics company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. Seres’ SER-109 program achieved the first-ever positive pivotal clinical results for a targeted microbiome drug candidate and has obtained Breakthrough Therapy and Orphan Drug designations from the FDA. The SER-109 program is being advanced for the treatment of recurrent C. difficile infection and has potential to become a first-in-class FDA-approved microbiome therapeutic. Seres is evaluating SER-301 in a Phase 1b study in patients with ulcerative colitis and SER-155 in a Phase 1b study to address gastrointestinal infections, bacteremia and graft-versus-host disease. For more information, please visit www.serestherapeutics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210805005036/en/

FAQ

When will Seres Therapeutics present at the Canaccord Genuity conference?

Seres Therapeutics will present on August 11 at 9:00 a.m. ET.

What is the ticker symbol for Seres Therapeutics?

The ticker symbol for Seres Therapeutics is MCRB.

What is SER-109 and its significance?

SER-109 is a microbiome drug candidate that achieved the first-ever positive pivotal clinical results and aims to treat recurrent C. difficile infection.

How long will the webcast replay of the conference be available?

The webcast replay will be available for approximately 21 days after the event.

What other programs is Seres Therapeutics currently developing?

Seres is also developing SER-301 for ulcerative colitis and SER-155 for gastrointestinal infections and graft-versus-host disease.